Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Fab-linked glycans as biomarker for the transition from a pre-disease “at-risk-phase” to rheumatoid arthritis; AAV or Sjögren syndrome

Fab-linked glycans as biomarker for the transition from a pre-disease “at-risk-phase” to rheumatoid arthritis; AAV or Sjögren syndrome

US Patent 12158468 · Granted Dec 3, 2024

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Compositions and methods for the diagnosis of rheumatoid arthritis2020
Anti-carbamylated protein antibodies and the risk for arthritis2020
Anti-carbamylated protein antibodies and the risk for arthritis2020
Anti-carbamylated protein antibodies and the risk for arthritis2020
Long peptides of 22-45 amino acid residues that induce and/or enhance antigen sp2019
Anti-carbamylated protein antibodies and the risk for arthritis2018
Anti-carbamylated protein antibodies and the risk for arthritis2018
Anti-carbamylated protein antibodies and the risk for arthritis2018
Compositions and methods for the diagnosis of rheumatoid arthritis2017
Long peptides of 22-45 amino acid residues that induce and/or enhance antigen sp2017
Anti-carbamylated protein antibodies and the risk for arthritis2017
Anti-carbamylated protein antibodies and the risk for arthritis2017